-Reuters
Verve Therapeutics Reported New Preclinical Data In Non-human Primates Demonstrating Potent, Durable, And Well-tolerated Editing Of The ANGPTL3 Gene Following The Administration Of VERVE-201
VERVE-201 aims to reduce the heavy treatment burden associated with available therapies for HoFH including the requirement for multiple oral, injectable, and intravenous infusions in each patient, often administered over
